zirconium Zr 89-DFO-vandortuzumab vedotin

{
  "id": "MLC-T-ONC-017692",
  "term": "zirconium Zr 89-DFO-vandortuzumab vedotin",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1) that can potentially be used as a prostate cancer tracer during positron emission tomography (PET). Upon administration of zirconium Zr 89-DFO-vandortuzumab vedotin, the antibody moiety DFO-vandortuzumab vedotin binds to STEAP1 on prostate cancer cells. In turn, Zr 89 allows for the visualization of those cells using PET. STEAP1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells.",
  "synonyms": [
    "zirconium Zr 89 DFO-MSTP2109A",
    "89Zr-DFO-vandortuzumab vedotin",
    "89Zr-DFO-MSTP2109A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zirconium-zr-89-dfo-vandortuzumab-vedotin/"
}